Granted Patent
B2
US 12,239,646 · App. 16/632,368 · Granted Mar 4, 2025
Cancer diagnostic and treatment
Assignee:
DANA-FARBER CANCER INSTITUTE, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Bacterial species and the associated microbiome persist in tumors and metastases. Antibiotic treatment selectively reduces microbiome-induced tumor growth and can advantageously be included in treatment regimens. Accordingly, the present disclosure relates to, for example, the diagnosing cancer in a subject and providing identifying an effective treatment regimen for the subject.
Claims (34)
1. A method of treating or preventing infection in a subject having a detectable colorectal Fusobacterium infection comprising:
administering systemically 5-fluorouracil or an analogue thereof, or a prodrug of 5-flurouracil or analogue thereof to the subject.
2. The method of claim 1 , further comprising detecting a Fusobacteria infection in the subject.
3. The method of claim 1 , wherein the detectable Fusobacterium infection is an invasive Fusobacterium infection and wherein the infection is treated systemically.
4. The method of claim 2 , further comprising detecting a co-occurring bacterial infection, wherein the co-occurring bacterial infection comprises a gram negative bacterial infection, an anaerobic bacterial infection, or both.
5. The method of claim 1 , wherein the subject suffers from a primary colorectal cancer tumor and/or a distant colorectal metastases.
6. The method of claim 4 , wherein the co-occurring bacterial infection further comprises bacteria of the genus Selenomonas, Prevotella , or any combination thereof.
7. The method of claim 1 , wherein the detectable Fusobacterium comprises Fusobacterium necrophorum.
8. The method of claim 1 , wherein the subject has a detectable co-occurring bacterial infection.
9. The method of claim 8 , wherein the detectable co-occurring bacterial infection is an anerobic bacterial infection, a gram negative bacterial infection, or both.
10. The method of claim 1 , further comprising detecting Fusobacteria in a sample, optionally a stool sample from the subject in need thereof.
11. The method of claim 1 , further comprising detecting Fusobacteria nucleic acids in a sample from the subject in need thereof, wherein the sample is optionally a stool sample or a bodily fluid sample.
12. The method of claim 11 , wherein the Fusobacteria nucleic acids are circulating nucleic acids.
13. The method of claim 11 , wherein detection comprises use of a CRISPR effector system.
14. The method of claim 1 , further comprising co-administering an antimicrobial agent comprising a Fusobacterium -selective antimicrobial agent, to the subject in need thereof.
15. The method of claim 1 , wherein a 5-fluorouracil analogue is administered to the subject.
16. The method of claim 1 , further comprising consuming a diet low in fat, low in lipid, low in carbohydrate, high in dietary fiber, or any combination thereof.
17. The method of claim 14 , wherein the antimicrobial agent comprises penicillin, clindamycin, chloramphenicol, metronidazole, erythromycin, a macrolide, or any combination thereof.
18. The method of claim 9 , wherein the gram-negative bacterial infection or the anerobic bacterial infection comprise bacteria from the genus Selenomonas, Bacteroides, Prevotella , or any combination thereof.
19. The method of claim 18 , wherein
(a) the Bacteroides genus bacteria comprise Bacterioides fragilis , Bacterioides helcogenes , Bacterioides salanitronis , or any combination thereof;
(b) the Selenomonas genus bacteria comprise Selenomonas ruminantium, Selenomonas sputigena , or both;
(c) the Prevotella genus bacteria comprise Prevotella denticola, Prevotella intermedia , or both; or
(d) any combination of (a)-(c).
20. The method of claim 6 wherein
(a) the Bacteroides genus bacteria comprise Bacterioides fragilis , Bacterioides helcogenes , Bacterioides salanitronis , or any combination thereof;
(b) the Selenomonas genus bacteria comprise Selenomonas ruminantium, Selenomonas sputigena , or both;
(c) the Prevotella genus bacteria comprise Prevotella denticola, Prevotella intermedia , or both; or
(d) any combination of (a)-(c).
21. The method of claim 15 , wherein the analogue is 1-hexylcarbamoyl-5-fluorouracil.
22. The method of claim 5 , wherein the primary colorectal cancer tumor is a proximal colorectal cancer tumor.
23. The method of claim 5 , wherein the distant colorectal metastases is a liver metastases or an abdominal wall metastases.
24. A method of treating or preventing infection in a subject having a detectable colorectal Fusobacterium infection consisting of:
administering systemically 5-fluorouracil or an analogue thereof, or a prodrug of 5-flurouracil or analogue thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 11, 2020
From: MEYERSON, MATTHEW
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 052920/0422 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 11, 2020
From: BULLMAN, SUSAN
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 052920/0444 →
Continuity (2)
Provisional Application
62534672
· Jul 19, 2017
References Cited (225)
US 3326761A
· Kent
· 1967
[cited by applicant]
US 4971903A
· Hyman
· 1990
[cited by applicant]
US 5202231A
· Drmanac et al.
· 1993
[cited by applicant]
US 5403708A
· Brennan et al.
· 1995
[cited by applicant]
US 5445934A
· Fodor et al.
· 1995
[cited by applicant]
US 5525464A
· Drmanac et al.
· 1996
[cited by applicant]
US 5547839A
· Dower et al.
· 1996
[cited by applicant]
US 5695940A
· Drmanac et al.
· 1997
[cited by applicant]
US 5795782A
· Church et al.
· 1998
[cited by applicant]
US 5902723A
· Dower et al.
· 1999
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 8771945B1
· Zhang
· 2014
[cited by applicant]
US 8795965B2
· Zhang
· 2014
[cited by applicant]
US 8865406B2
· Zhang et al.
· 2014
[cited by applicant]
US 8871445B2
· Cong et al.
· 2014
[cited by applicant]
US 8889356B2
· Zhang
· 2014
[cited by applicant]
US 8889418B2
· Zhang et al.
· 2014
[cited by applicant]
US 8895308B1
· Zhang et al.
· 2014
[cited by applicant]
US 8906616B2
· Zhang et al.
· 2014
[cited by applicant]
US 8932814B2
· Cong et al.
· 2015
[cited by applicant]
US 8945839B2
· Zhang
· 2015
[cited by applicant]
US 8993233B2
· Zhang et al.
· 2015
[cited by applicant]
US 8999641B2
· Zhang et al.
· 2015
[cited by applicant]
US 20100029498A1
· Gnirke et al.
· 2010
[cited by applicant]
US 20100040614A1
· Ahmed
· 2010
[cited by applicant]
US 20130230857A1
· Gnirke et al.
· 2013
[cited by applicant]
US 20140170753A1
· Zhang
· 2014
[cited by applicant]
US 20140179770A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140186843A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140186919A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140189896A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140228223A1
· Gnirke et al.
· 2014
[cited by applicant]
US 20140242664A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140242699A1
· Zhang
· 2014
[cited by applicant]
US 20140310830A1
· Zhang et al.
· 2014
[cited by applicant]
US 20150126377A1
· Gnirke et al.
· 2015
[cited by applicant]
US 20160220619A1
· Lee
· 2016
[cited by applicant]
EP 2764103B1
· 2014
[cited by applicant]
EP 2771468B1
· 2014
[cited by applicant]
EP 2784162B1
· 2014
[cited by applicant]
WO WO9323564A1
· 1993
[cited by applicant]
WO WO9639154A1
· 1996
[cited by applicant]
WO WO9703211A1
· 1997
[cited by applicant]
WO WO9813523A1
· 1998
[cited by applicant]
WO WO9828440A1
· 1998
[cited by applicant]
WO WO2009099602A1
· 2009
[cited by applicant]
WO WO2014018423A1
· 2014
[cited by applicant]
WO WO2014047556A1
· 2014
[cited by applicant]
WO WO2014093595A1
· 2014
[cited by applicant]
WO WO2014093622A2
· 2014
[cited by applicant]
WO WO2014093635A1
· 2014
[cited by applicant]
WO WO2014093655A2
· 2014
[cited by applicant]
WO WO2014093661A2
· 2014
[cited by applicant]
WO WO2014093694A1
· 2014
[cited by applicant]
WO WO2014093701A1
· 2014
[cited by applicant]
WO WO2014093709A1
· 2014
[cited by applicant]
WO WO2014093712A1
· 2014
[cited by applicant]
WO WO2014093718A1
· 2014
[cited by applicant]
WO WO2014204723A1
· 2014
[cited by applicant]
WO WO2014204724A1
· 2014
[cited by applicant]
WO WO2014204725A1
· 2014
[cited by applicant]
WO WO2014204726A1
· 2014
[cited by applicant]
WO WO2014204727A1
· 2014
[cited by applicant]
WO WO2014204728A1
· 2014
[cited by applicant]
WO WO2014204729A1
· 2014
[cited by applicant]
Beyaz et al. “High-fat diet enhances stemness and tumorigenicity of intestinal progenitors,” Nature 531, 54. (Year: 2016).
[cited by examiner]
Yu et al. “Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway,” Int. J. Cancer: 139, 1318-1326 (2016). (Year: 2016).
[cited by examiner]
Wilhelm et al. “Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice,” Clinical Colorectal Cancer, vol. 15, No. 4, 381-8; (Yea…
[cited by examiner]
Vanlancker et al. “5-Fluorouracil sensitivity varies among oral microorganisms,” Journal of Medical Microbiology (2016), 65, 775-783. (Year: 2016).
[cited by examiner]
Beyaz et al. “High-fat diet enhances stemness and tumorigenicity of intestinal progenitors,” Nature 2016, 531, 54. (Year: 2016).
[cited by examiner]
International Search Report for PCT/US2018/042966 issued by the U.S. Patent Office, as International Searching Authority on Nov. 15, 2018.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT/US2018/042966 issued by the U.S. Patent Office, as International Searching Authority on Nov. 15, 2018.
[cited by applicant]
“ChandraPedamallu / PathSeq”, https://github.com/ChandraPedamallu/P, downloaded from the internet Jan. 15, 2020.
[cited by applicant]
Abed, et al., “Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc”, Cell Host and Microbe, vol. 20, No. 2, Aug. 10, 2016, 215-225.
[cited by applicant]
Ahn, et al., “Human Gut Microbiome and Risk for Colorectal Cancer”, Journal of the National Cancer Institute, vol. 105, No. 24, Dec. 18, 2013, 1907-1911.
[cited by applicant]
Altschul, et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs”, Nucleic Acids Research, vol. 25, No. 17, Sep. 1997, 3389-3402.
[cited by applicant]
Ananthakrishnan, et al., “A Prospective Study of Long-term Intake of Dietary Fiber and Risk of Crohn's Disease and Ulcerative Colitis”, Gastroenterology, vol. 145, No. 5, Nov. 2013, 970-977.
[cited by applicant]
Arthur, et al., “Intestinal Inflammation Targets Cancer-Inducing Activity of The Microbiota”, Science, vol. 338, No. 6103, Oct. 5, 2012, 120-123.
[cited by applicant]
Aune, et al., “Dietary Fibre, Whole Grains, and Risk of Colorectal Cancer: Systematic Review and Dose-response Meta-analysis of Prospective Studies”, BMJ, vol. 343, 2011, 20 pages.
[cited by applicant]
Aziz, et al., “The Rast Server: Rapid Annotations Using Subsystems Technology”, BMC Genomics, vol. 9, Feb. 8, 2008, 1-15.
[cited by applicant]
Cancer Genome Atlas Network, “Comprehensive Molecular Characterization of Human Colon and Rectal Cancer”, Nature, vol. 4807, No. 7407, Jul. 18, 2012, 330-337.
[cited by applicant]
Castellarin, et al., “Fusobacterium Nucleatum Infection is Prevalent in Human Colorectal Carcinoma”, Genome Research, vol. 22, No. 2, Feb. 2012, 299-306.
[cited by applicant]
Chen, et al., “Decreased Dietary Fiber Intake and Structural Alteration of Gut Microbiota in Patients with Advanced Colorectal Adenoma”, The American Journal of Clinical Nutrition, vol. 97, No. 5, May 2013, 1044-1052.
[cited by applicant]
Claesson, et al., “Gut Microbiota Composition Correlates with Diet and Health in the Elderly”, Nature, vol. 488, No. 7410, Jul. 2012, 178-184.
[cited by applicant]
Cotillard, et al., “Dietary Intervention Impact on Gut Microbial Gene Richness”, Nature, vol. 500, No. 7464, Aug. 2013, 558-588.
[cited by applicant]
Cottet, et al., “Dietary Patterns and the Risk of Colorectal Adenoma Recurrence in a European Intervention Trial”, European Journal of Cancer Prevention, vol. 14, No. 1, 21-29., Feb. 1, 2005.
[cited by applicant]
De Filippis, et al., “High-level Adherence to a Mediterranean Diet Beneficially Impacts the Gut Microbiota and Associated Metabolome”, Gut, vol. 65, No. 11, Nov. 2016, 1812-1821.
[cited by applicant]
Dejea, et al., “Microbiota Organization is a Distinct Feature of Proximal Colorectal Cancers”, Proceedings of the National Academy of Sciences of the United States of America, vol. 111, No. 51, Dec. 23, 2014, 18321-1832…
[cited by applicant]
Destefano Shields, et al., “Reduction of Murine Colon Tumorigenesis Driven by Enterotoxigenic Bacteroides fragilis Using Cefoxitin Treatment”, The Journal of Infectious Disease, vol. 214, pp. 122-129.
[cited by applicant]
Durbin, et al., “Fast and Accurate Short Read Alignment with Burrows-Wheeler Transform”, Bioinformatics Oxford English, vol. 25, No. 14, May 12, 2009, 1754-1760.
[cited by applicant]
Flanagan, et al., “Fusobacterium Nucleatum Associates with Stages of Colorectal Neoplasia Development, Colorectal Cancer and Disease Outcome”, European Journal of Clinical Microbiology & Infectious Diseases, vol. 33, No…
[cited by applicant]
Flemer, et al., “Tumour-associated and non-tumour-associated microbiota in colorectal cancer”, Gut Microbiota, Mar. 15, 2015, pp. 1-11.
[cited by applicant]
Flood, et al., “Dietary Patterns as Identified by Factor Analysis and Colorectal Cancer among Middle-Aged Americans”, The American Journal of Clinical Nutrition, vol. 88, No. 1, Jul. 2008, 176-184.
[cited by applicant]
Fu, et al., “Characterization of the Gut Microbiome in Epidemiologic Studies: The Multiethnic Cohort Experience”, Annals of Epidemiology, vol. 26, No. 5, May 2016, 373-379.
[cited by applicant]
Fung, et al., “Major Dietary Patterns and the Risk of Colorectal Cancer in Women”, Archives of Internal Medicine, vol. 163, No. 3, Feb. 10, 2003, 309-314.
[cited by applicant]
Garrett, “Cancer and the Microbiota”, Science, vol. 348, No. 6230, Apr. 3, 2015, 80-86.
[cited by applicant]
Gire, et al., “Genomic Surveillance Elucidates Ebola Virus Origin and Transmission During The 2014 Outbreak”, Science, vol. 345, No. 6202, Sep. 12, 2014, 1369-1372.
[cited by applicant]
Grant, et al., “The CGView Server: A Comparative Genomics Tool for Circular Genomes”, Nucleic Acids Research, vol. 36, Jul. 1, 2008, W181-W184.
[cited by applicant]
Gur, et al., “Binding of The Fap2 Protein of Fusobacterium Nucleatum to Human Inhibitory Receptor Tigit Protects Tumors from Immune Cell Attack”, Immunity, vol. 42, No. 2, Feb. 17, 2015, 344-355.
[cited by applicant]
Hamada, et al., “Molecular Pathological Epidemiology: New Developing Frontiers of Big Data Science to Study Etiologies and Pathogenesis”, Journal of Gastroenterology, vol. 52, No. 3, Mar. 2017, 265-275.
[cited by applicant]
Hope, et al., “Sporadic Colorectal Cancer—Role of The Commensal Microbiota”, FEMS Microbiology Letters, vol. 244, No. 1, Mar. 1, 2005, 1-7.
[cited by applicant]
Hu, et al., “Prospective Study of Major Dietary Patterns and Risk of Coronary Heart Disease in Men”, The American Journal of Clinical Nutrition, vol. 72, 2000, 92-921.
[cited by applicant]
Ito, et al., “Association of Fusobacterium Nucleatum with Clinical and Molecular Features in Colorectal Serrated Pathway”, International Journal of Cancer, vol. 137, No. 6, Sep. 2015, 1258-1268.
[cited by applicant]
Kim, et al., “Dietary Patterns and Subsequent Colorectal Cancer Risk by Subsite: A Prospective Cohort Study”, International Journal of Cancer, vol. 115, No. 5, Jul. 10, 2005, 790-798.
[cited by applicant]
Koeth, et al., “Intestinal Microbiota Metabolism of L-carnitine, a Nutrient in Red Meat, Promotes Atherosclerosis”, Nature Medicine, vol. 19, No. 5, May 2013, 576-585.
[cited by applicant]
Kolenbrander, “Adhere Today, Here Tomorrow: Oral Bacterial Adherence”, Journal of Bacteriology, vol. 175, No. 11, Jun. 1993, 3247-325.
[cited by applicant]
Kolenbrander, “Coaggregation of Fusobacterium Nucleatum, Selenomonas Flueggei, Selenomonas Infelix, Selenomonas Noxia, and Selenomonas Sputigena with Strains From 11 Genera of Oral Bacteria”, Infection and Immunity, vol…
[cited by applicant]
Kolenbrander, et al., “Inhibition of Coaggregation between Fusobacterium Nucleatum and Porphyromonas (Bacteroides) Gingivalis by Lactose and Related Sugars”, Infection and Immunity, vol. 57, No. 10, Oct. 1989, 3204-3209.
[cited by applicant]
Kostic, et al., “Fusobacterium Nucleatum Potentiates Intestinal Tumorigenesis and Modulates The Tumor-Immune Microenvironment”, Cell Host and Microbe, vol. 14, No. 2, Aug. 14, 2013, 207-215.
[cited by applicant]
Kostic, et al., “Genomic Analysis Identifies Association of Fusobacterium with Colorectal Carcinoma”, Genome Research, vol. 22, No. 2, Feb. 2012, 292-298.
[cited by applicant]
Kostic, et al., “Pathseq: Software to Identify or Discover Microbes by Deep Sequencing of Human Tissue”, Nature Biotechnology, vol. 29, No. 5, May 2011, 393-396.
[cited by applicant]
Le Chatelier, et al., “Richness of Human Gut Microbiome Correlates with Metabolic Markers”, Nature, vol. 500, Aug. 2013, 541-546.
[cited by applicant]
Li, et al., “Association of Fusobacterium Nucleatum Infection with Colorectal Cancer in Chinese patients”, World Journal of Gastroenterology, vol. 22, No. 11, Mar. 21, 2016, 3227-3233.
[cited by applicant]
Lofmark, et al., “Metronidazole is still the Drug Of Choice for Treatment of Anaerobic Infections”, Clinical Infectious Diseases, vol. 50, Jan. 1, 2010, S16-S23.
[cited by applicant]
Magalhaes, et al., “Dietary Patterns and Colorectal Cancer: Systematic Review and Meta-analysis”, European Journal of Cancer Prevention, vol. 21, No. 1, Jan. 2012, 15-23.
[cited by applicant]
Markowitz, et al., “IMG ER: A System for Microbial Genome Annotation Expert Review and Curation”, Bioinformatics, vol. 25, No. 17, Sep. 1, 2009, 2271-2278.
[cited by applicant]
Martin, “Quantitative Microbiological Study of Human Carious Dentine by Culture and Real-Time PCR: Association of Anaerobes with Histopathological Changes in Chronic Pulpitis”, Journal of Clinical Microbiology, vol. 40,…
[cited by applicant]
McCoy, et al., “Fusobacterium is associated with Colorectal Adenoma”, PLoS One, vol. 8, No. 1, Jan. 15, 2013, 8 pages.
[cited by applicant]
Microbewiki, “Fusobacterium Nucleatum”, https://microbewiki.kenyon.edu/index.php?title+Fusobacterium_nucleatum&oldid=54788.
[cited by applicant]
Mima, et al., “Fusobacterium Nucleatum and T Cells in Colorectal Carcinom”, JAMA Oncology, vol. 1, No. 5, Aug. 2015, 653-661.
[cited by applicant]
Mima, et al., “Fusobacterium Nucleatum in Colorectal Carcinoma Tissue According to Tumor Location”, Clinical and Translational Gastroenterology, vol. 7, No. 11, 2016, 8 pages.
[cited by applicant]
Mima, et al., “Fusobacterium Nucleatum in Colorectal Carcinoma Tissue and Patient Prognosis”, Gut, vol. 65, No. 12, Dec. 2016, 1973-1980.
[cited by applicant]
Mizoue, et al., “Dietary Patterns and Colorectal Adenomas in Japanese Men: The Self-Defense Forces Health Study”, American Journal of Epidemiology, vol. 116, No. 4, 2005, 338-345.
[cited by applicant]
Nakatsu, et al., “Gut Mucosal Microbiome across Stages of Colorectal Carcinogenesis”, Nature Communications, vol. 6, Oct. 30, 2015, 1-9.
[cited by applicant]
Nosho, et al., “Association of Fusobacterium Nucleatum with Immunity and Molecular Alterations in Colorectal Cancer”, World Journal of Gastroenterology, vol. 22, No. 2, Jan. 2016, 557-566.
[cited by applicant]
Ogino, et al., “Molecular Pathologic Epidemiology of Colorectal Neoplasia: An Emerging Transdisciplinary and Interdisciplinary Field”, Gut, vol. 60, No. 3, Mar. 2011, 397-411.
[cited by applicant]
Ogino, et al., “The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-Neoplastic Diseases in the Era of Precision Medicine”, Epidemiology, vol. 27, No. 4, Jul. 27, 2016, 602-611.
[cited by applicant]
O'Keefe, et al., “Fat, Fibre and Cancer Risk in African Americans and Rural Africans”, Nature Communications, vol. 6, Article No. 6342, 2015, 14 pages.
[cited by applicant]
Ou, et al., “Diet, Microbiota, and Microbial Metabolites in Colon Cancer Risk in Rural Africans and African Americans”, The American Journal of Clinical Nutrition, vol. 98, Issue 1, Jul. 2013, 111-120.
[cited by applicant]
Rimm, et al., “Reproducibility and Validity of an Expanded Self-Administered Semiquantitative Food Frequency Questionnaire among Male Health Professionals”, American Journal of Epidemiology, vol. 135, No. 10, Jun. 1992,…
[cited by applicant]
Rowland, “The Role of the Gastrointestinal Microbiota in Colorectal Cancer”, Current Pharmaceutical Design, vol. 15, No. 13, 2009, 1524-1527.
[cited by applicant]
Rubinstein, et al., “Fusobacterium Nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/B- Catenin Signaling Via Its Fada Adhesin”, Cell Host and Microbe, vol. 14, No. 2, Aug. 14, 2013, 195-206.
[cited by applicant]
Schwabe, et al., “The Microbiome and Cancer”, Nature Reviews Cancer, vol. 13, No. 11, Nov. 2013, 800-812.
[cited by applicant]
Segata, et al., “Metagenomic Biomarker Discovery and Explanation”, Genome Biology, vol. 12, No. 60, Jun. 24, 2011, 1-18.
[cited by applicant]
Shields, et al., “Reduction of Murine Colon Tumorigenesis Driven by Enterotoxigenic Bacteroides fragilis Using Cefoxitin Treatment”, The Journal of Infectious Diseases, vol. 214, Issue 1, Jul. 1, 2016, 122-129.
[cited by applicant]
Sinha, et al., “Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations”, Plos One, vol. 11, No. 3, Mar. 25, 2016, 1-13.
[cited by applicant]
Smith, et al., “The Microbial Metabolites, Short-chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis”, Science, vol. 341, No. 6145, Aug. 2013, 569-573.
[cited by applicant]
Song, et al., “Nutrients, Foods, and Colorectal Cancer Prevention”, Gastroenterology, vol. 148, No. 6, May 2015, 1244-1260.
[cited by applicant]
Sonnenburg, et al., “Diet-induced Extinction in the Gut Microbiota Compounds Over Generations”, Nature, vol. 529, No. 7585, Jan. 14, 2016, 212-215.
[cited by applicant]
Tahara, et al., “Fusobacterium in Colonic Flora and Molecular Features of Colorectal Carcinom”, Cancer Research, vol. 74, No. 5, Mar. 1, 2014, 1311-1318.
[cited by applicant]
Takimoto, et al., “High Inter- and Intrapatient Variation in 5-Fluorouracil Plasma Concentrations during a Prolonged Drug Infusion”, Clinical Cancer Research, vol. 5, Issue 6, Jun. 1999, 1347-1352.
[cited by applicant]
Terry, et al., “Prospective Study of Major Dietary Patterns and Colorectal Cancer Risk in Women”, American Journal of Epidemiology, vol. 154, Issue 12, Dec. 15, 2001, 1143-1149.
[cited by applicant]
Tuddenham, et al., “The Intestinal Microbiome and Health”, Current Opinion in Infectious Diseases, vol. 28, No. 5, 2015, 464-470.
[cited by applicant]
Viljoen, et al., “Quantitative Profiling of Colorectal Cancer-Associated Bacteria Reveals Associations between
[cited by applicant]
Wang, et al., “Statistical Methods for Studying Disease Subtype Heterogeneity”, Statistics in Medicine, vol. 35, No. 5, Feb. 28, 2016, 782-800.
[cited by applicant]
Warren, et al., “Co-Occurrence of Anaerobic Bacteria in Colorectal Carcinomas”, Microbiome, vol. 1, No. 1, May 15, 2013, 12 pages.
[cited by applicant]
World Cancer Research Fund, “Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer”, American Institute for Cancer Research, Colorectal Cancer Report 2011, 2011, 43 pages.
[cited by applicant]
Wu, et al., “A Human Colonic Commensal Promotes Colon Tumorigenesis Via Activation of T Helper type 17 T Cell Responses”, Nature Medicine, vol. 15, No. 9, Sep. 2009, 1016-1022.
[cited by applicant]
Wu, et al., “Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes”, Science, vol. 334, No. 6052, Oct. 2011, 105-108.
[cited by applicant]
Yang, et al., “Bacteria, Inflammation, and Colon Cancer”, World Journal of Gastroenterology, vol. 12, No. 42, Nov. 14, 2006, 6741-6746.
[cited by applicant]
Yang, et al., “Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of …
[cited by applicant]
Zerbino, et al., “Velvet: Algorithms for De Novo Short Read Assembly Using De Bruijn Graphs”, Genome Research, vol. 18, No. 5, May 2008, 821-829.
[cited by applicant]
Altschul et al., “Basic local alignment search tool,” Journal of Molecular Biology, 1990, vol. 215 (pp. 403-410).
[cited by applicant]
Bass et al., “Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion,” Nature Genetics, 2011, vol. 43, No. 10 (pp. 964-968).
[cited by applicant]
Canard et al., “DNA polymerase fluorescent substrates with reversible 3′-tags,” Gene, Oct. 11, 1994, vol. 148, No. 1 (pp. 1-6).
[cited by applicant]
Chen et al., “Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis,” Cell, 2015 vol. 160 (pp. 1-15).
[cited by applicant]
Chung et al., “Structural and molecular interrogation of intact biological systems,” Nature, May 16, 2013, vol. 497 (pp. 332-337).
[cited by applicant]
Cong et al., “CRISPR-Assisted Mammalian Genome Engineering,” published as “Multiplex Genome Engineering Using CRISPR-Cas Systems,” Science, Oct. 5, 2012, vol. 339 (pp. 819-823) [Manuscript including Supplementary Materi…
[cited by applicant]
Dahlman et al., “Orthogonal gene control with a catalytically active Cas9 nuclease,” Nature Biotechnology, Nov. 2015, vol. 33, No. 11 (pp. 1159-1161).
[cited by applicant]
Doench et al., “Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation,” Nature Biotechnology, 2014, vol. 32 (pp. 1262-1267) [including Supplementary Material, 17 pages].
[cited by applicant]
Drmanac et al., “Sequencing of megabase plus DNA by hybridization: theory of the method,” Genomics, Feb. 1989, vol. 4, No. 2 (pp. 114-128).
[cited by applicant]
Dyatkina et al., “Terminating substrates of DNA polymerases: synthesis and functional study,” Nucleic Acids Symposium Series, Jan. 1, 1987, vol. 18 (pp. 117-120).
[cited by applicant]
Elgen et al., “Sorting single molecules: application to diagnostics and evolutionary biotechnology,” Proceedings of the National Academy of Sciences, USA, Jun. 1994, vol. 91 (pp. 55740-5747).
[cited by applicant]
Empedocles et al., “Three-dimensional orientation measurements of symmetric single chromophores using polarization microscopy,” Nature, 1999, vol. 399 (pp. 126-130).
[cited by applicant]
Gao et al., “Engineered Cpf1 enzymes with altered PAM specificities,” bioRxiv preprint, Dec. 4, 2016 [pp. 1/14-14/14, pp. 1/3-3/3 of Figs, and pp. S1-S8 (25 pages)].
[cited by applicant]
Geniez et al., “Targeted genome enrichment for efficient purification of endosymbiont DNA from host DNA,” Symbiosis, Jan. 6, 2013, vol. 58 (pp. 201-207).
[cited by applicant]
Gire et al., “Genomic Surveillance Elucidates Ebola Virus Origin and Transmission During The 2014 Outbreak”, Science, Sep. 12, 2014, vol. 345, No. 6202 (pp. 1369-1372).
[cited by applicant]
Gnirke et al., “Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing,” Nature Biotechnology, Feb. 2009, vol. 27, No. 2 (pp. 182-189).
[cited by applicant]
Gootenberg et al., “Nucleic acid detection with CRISPR-Cas13a/C2c2,” Science, Apr. 28, 2017, vol. 356 (pp. 438-442).
[cited by applicant]
Hsu et al., “Development and Applications of CRISPR-Cas9 for Genome Engineering,” Cell, 2014, vol. 157 (pp. 1262-1278).
[cited by applicant]
Hsu et al., “DNA targeting specificity of RNA-guided Cas9 nucleases,” Nature Biotechnology, Sep. 2013, vol. 31, No. 9 (pp. 827-832).
[cited by applicant]
Hyman et al., “A new method of sequencing DNA,” Analytical Biochemistry, Nov. 1, 1988, vol. 174, No. 2 (pp. 423-436).
[cited by applicant]
Jiang et al., “RNA-guided editing of bacterial genomes using CRISPR-Cas systems,” Nature Biotechnology, Mar. 2013, vol. 31 [30 pages, including supplementary information] (pp. 233-239).
[cited by applicant]
Johnson et al., “Continuous assay for DNA polymerization by light scattering,” Analytical Biochemistry, Jan. 1984, vol. 136, No. 1 (pp. 192-194).
[cited by applicant]
Jones, D.H., “An iterative and regenerative method for DNA sequencing,” BioTechniques, May 1997, vol. 22 (pp. 938-946).
[cited by applicant]
Konermann et al., “Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex,” Nature, 2015, vol. 517 (pp. 583-588) [Including Supplemental information, 12 pages].
[cited by applicant]
Konermann et al., “Optical control of mammalian endogenous transcription and epigenetic states,” Nature, Aug. 22, 2013, vol. 500, Includes Supplemental Information (pp. 472-476).
[cited by applicant]
Koster et al., “A strategy for rapid and efficient DNA sequencing by mass spectrometry,” Nature Biotechnology, Sep. 1996, vol. 14 (pp. 1123-1128).
[cited by applicant]
Lane, D.J., “16S/23S rRNA sequencing,” Nucleic acid techniques in bacterial systematics, Nucleic Acid Techniques in Bacterial Systematics, Chapter 6, 1991 (pp. 125-175).
[cited by applicant]
Matranga et al., “Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples,” Genome Biology, 2014, vol. 15, No. 519 (pp. 1-12).
[cited by applicant]
Melnikov et al., “Hybrid selection for sequencing pathogen genomes from clinical samples,” Genome Biology, Aug. 11, 2011, vol. 12, No. R73, (pp. 1-9).
[cited by applicant]
Metzker et al., “Termination of DNA synthesis by novel 3′-modifieddeoxyribonucleoside 5′-triphosphates,” Nucleic Acids Research, 1994, vol. 22, No. 20 (pp. 4259-4267).
[cited by applicant]
Nishimasu et al., “Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA,” Cell, Feb. 27, 2014, vol. 156 (pp. 935-949).
[cited by applicant]
Nishimasu et al., “Crystal Structure of
[cited by applicant]
Nyren et al., “Enzymatic method for continuous monitoring of inorganic pyrophosphate synthesis,” Analytical Biochemistry, Dec. 1985, vol. 151, No. 2 (pp. 504-509).
[cited by applicant]
Parnas et al., “A Genome-Wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks,” 2015, vol. 162 (pp. 675-686) [with Supplementary Information].
[cited by applicant]
Platt et al., “CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling,” Cell, 2014, vol. 159 (pp. 440-455).
[cited by applicant]
Ramanan et al., “CRISPR-Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus,” Nature/Scientific Reports, Jun. 2015 (9 pages).
[cited by applicant]
Ran et al., “Double Nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity”, Cell, Sep. 12, 2013, vol. 154 (pp. 1380-1389).
[cited by applicant]
Ran et al., “Genome engineering using the CRISPR-Cas9 system,” Nature Protocols, 2013, vol. 8 (pp. 2281-2308).
[cited by applicant]
Ran et al., “In vivo genome editing using
[cited by applicant]
Reichert et al., “Chip-Based Optical Detection of DNA Hybridization by Means of Nanobead Labeling,” Analytical Chemistry, Dec. 15, 2000, vol. 72, No. 24 (pp. 6025-6029).
[cited by applicant]
Ronaghi et al., “A Sequencing Method Based on Real-Time Pyrophosphate,” Science, Jul. 17, 1988, vol. 281, No. 5375 (pp. 363-365).
[cited by applicant]
Ronaghi et al., “Real-time DNA sequencing using detection of pyrophosphate release,” Analytical Biochemistry, 1996, vol. 242, Article 0432 (pp. 84-89).
[cited by applicant]
Sanger et al., “DNA sequencing with chain-terminating inhibitors,” Proceedings of the National Academy of Sciences, USA, Dec. 1977, vol. 74, No. 12 (pp. 5463-5467).
[cited by applicant]
Shalem et al., “Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells,” Science, Jan. 3, 2014, vol. 343 (pp. 84-87).
[cited by applicant]
Shalem et al., “High-throughput functional genomics using CRISPR-Cas9” Nature Review Genetics, 2015, vol. 16, No. 5 (pp. 299-311).
[cited by applicant]
Shiroguchi et al., “Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes,” Proceedings of the National Academy of Sciences, USA, Jan. 24, 2012, vol. 10…
[cited by applicant]
Shmakov et al., “Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems,” Molecular Cell, Nov. 1, 2015, vol. 60, No. 3 (pp. 385-397).
[cited by applicant]
Smargon et al., “Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNases Differentially Regulated by Accessory Proteins Csx27 and Csx28,” Cell Press: Molecular Cell, Feb. 16, 2017, vol. 65, No. 4 (pp. 618-630).
[cited by applicant]
Sorek et al., “A novel algorithm for computational identification of contaminated EST libraries,” Nucleic Acids Research, 2003, vol. 31, No. 3 (pp. 1067-1074).
[cited by applicant]
Swiech et al., “In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9,” Nature Biotechnology, 2014, vol. 33 (pp. 102-106) [Including Supplemental information, 4 pages].
[cited by applicant]
Wang et al., “Genetic screens in human cells using the CRISPR/Cas9 system,” Science, Jan. 3, 2014, vol. 343 No. 6166 (pp. 80-84).
[cited by applicant]
Wang et al., “One-Step Generation Of Mice Carrying Mutations In Multiple Genes By CRISPR/Cas-Mediated Genome Engineering,” Cell, May 9, 2013, vol. 153 (pp. 910-918).
[cited by applicant]
Weber et al., “Identification of foreign gene sequences by transcript filtering against the human genome,” Nature Genetics, Feb. 2002, vol. 30, Issue 2 (pp. 141-142)—(22 pages with Supplemental Information).
[cited by applicant]
Wu et al., “Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells,” Nature Biotechnology, 2014, Including Supplemental information, 2 pages (pp. 1-9).
[cited by applicant]
Xu et al., “Sequence determinants of improved CRISPR sgRNA design,” Genome Research, Aug. 2015, vol. 25 (pp. 1147-1157).
[cited by applicant]
Zetsche at el., “Cpfl Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System,” Cell, Oct. 22, 2015, vol. 163, No. 3 (pp. 759-771).
[cited by applicant]
Zetsche et al., “A split-Cas9 architecture for inducible genome editing and transcription modulation”, Nature Biotechnology, Feb. 2015, vol. 33, No. 2 (pp. 139-142).
[cited by applicant]